Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Salix S R L manages a company patent portfolio within the Biotechnology & Pharmaceuticals technology area. The portfolio currently includes 1 pending office action. This specific action is located in 1 distinct art unit. A practitioner managing this portfolio interacts with 1 distinct examiner to address the outstanding issues.
The busiest examiner for this entity is TRUONG, QUANGLONG N, who is currently responsible for 1 busiest examiner pending office action. This figure matches the total number of 1 pending office action for the entire portfolio. This means the prosecution workload is entirely handled by this examiner. Such a structure allows for a direct and consistent dialogue between the applicant and the USPTO.
Because the work is limited to 1 distinct art unit, the technical arguments required for these filings are specific to that unit's standards. The presence of 1 distinct examiner means that the legal strategy does not need to account for different examiner behaviors across the applications. The data shows a prosecution environment where all active matters are funneled through TRUONG, QUANGLONG N, which simplifies the administrative oversight of the Salix S R L company patent portfolio.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| TRUONG, QUANGLONG N | 1 | 78.6% | +23.3% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18286206 | SOLID MICROCAPSULE HAVING SELF-EMULSIFYING CAPACITY | TRUONG, QUANGLONG N | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18286206 | SOLID MICROCAPSULE HAVING SELF-EMULSIFYING CAPACITY | TRUONG, QUANGLONG N | — |
| Art Unit | Apps |
|---|---|
| 1615 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18286206 | SOLID MICROCAPSULE HAVING SELF-EMULSIFYING CAPACITY | TRUONG, QUANGLONG N | 1615 | §103§112 | Non-Final OA | — | Pending | Oct 09, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialSalix S R L has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Quanglong N Truong has the most, with 1 of Salix S R L's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
